J. Richard Hawkins's Insider Trades & SAST Disclosures
J. Richard Hawkins's most recent trade in Plus Therapeutics Inc was a trade of 40,122 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 18, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern J. Richard Hawkins.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Plus Therapeutics Inc | Richard J. Hawkins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 40,122 | 40,122 | - | - | Stock Option (Right to Buy) | |
| Savara Inc | Richard J. Hawkins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Dec 2024 | 40,000 | 75,241 (0%) | 0% | 0 | Common Stock | |
| Savara Inc | Richard J. Hawkins | Director | Sale of securities on an exchange or to another person at price $ 3.32 per share. | 12 Dec 2024 | 8,000 | 67,241 (0%) | 0% | 3.3 | 26,569 | Common Stock |
| Plus Therapeutics Inc | Richard J. Hawkins | Director | Purchase of securities on an exchange or from another person at price $ 1.50 per share. | 13 Sep 2024 | 4,000 | 15,188 (0%) | 0% | 1.5 | 5,996 | Common Stock |
| Plus Therapeutics Inc | Richard J. Hawkins | Director | Purchase of securities on an exchange or from another person at price $ 1.35 per share. | 12 Sep 2024 | 6,285 | 11,188 (0%) | 0% | 1.4 | 8,512 | Common Stock |
| Plus Therapeutics Inc | Richard J. Hawkins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Sep 2024 | 3,650 | 3,650 | - | - | Stock Option (Right to Buy) | |
| Plus Therapeutics Inc | Richard J. Hawkins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2024 | 9,804 | 9,804 | - | - | Warrants (Right to buy) | |
| Plus Therapeutics Inc | Richard J. Hawkins | Director | Purchase of securities on an exchange or from another person at price $ 2.04 per share. | 08 May 2024 | 4,902 | 4,903 (0%) | 0% | 2.0 | 10,000 | Common Stock |
| Lumos Pharma Inc | Richard J. Hawkins | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2024 | 35,400 | 35,400 | - | - | Stock Option (Right to Buy) | |
| Lumos Pharma Inc | Richard J. Hawkins | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 2.84 per share. | 01 Apr 2024 | 4,500 | 754,615 (2%) | 0% | 2.8 | 12,780 | Common Stock |
| Lumos Pharma Inc | Richard J. Hawkins | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.84 per share. | 01 Apr 2024 | 1,522 | 753,093 (2%) | 0% | 2.8 | 4,322 | Common Stock |
| Plus Therapeutics Inc | J. Richard Hawkins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2024 | 2,250 | 2,250 | - | - | Stock Option (Right to Buy) | |
| Lumos Pharma Inc | Richard Hawkins J. | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.01 per share. | 01 Feb 2024 | 690 | 750,115 (2%) | 0% | 3.0 | 2,077 | Common Stock |
| Savara Inc | Richard Hawkins J. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Dec 2023 | 22,500 | 35,241 (0%) | 0% | 0 | Common Stock | |
| Savara Inc | Richard Hawkins J. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Dec 2023 | 10,841 | 0 | - | - | Stock Option (Right to Buy) | |
| Savara Inc | Hawkins J. Richard | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.82 per share. | 11 Dec 2023 | 10,841 | 12,741 (0%) | 0% | 0.8 | 8,890 | Common Stock |
| Lumos Pharma Inc | Richard J. Hawkins | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.31 per share. | 01 Apr 2023 | 1,522 | 750,805 (2%) | 0% | 3.3 | 5,038 | Common Stock |
| Plus Therapeutics Inc | Richard J. Hawkins | Director | Purchase of securities on an exchange or from another person at price $ 1000.00 per share. | 03 Mar 2023 | 1 | 1 | - | 1000 | 1,000 | Series F Preferred Stock |
| Plus Therapeutics Inc | Richard J. Hawkins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2023 | 20,182 | 20,182 | - | - | Stock Option (Right to Buy) | |
| Lumos Pharma Inc | Richard J. Hawkins | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 35,400 | 35,400 | - | - | Stock Option (Right to Buy) | |
| Lumos Pharma Inc | Richard J. Hawkins | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 3.52 per share. | 01 Feb 2023 | 4,500 | 752,743 (2%) | 0% | 3.5 | 15,840 | Common Stock |
| Lumos Pharma Inc | Richard J. Hawkins | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.52 per share. | 01 Feb 2023 | 416 | 752,327 (2%) | 0% | 3.5 | 1,464 | Common Stock |
| Savara Inc | Richard J. Hawkins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Dec 2022 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Savara Inc | Richard J. Hawkins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Dec 2022 | 1,172 | 0 | - | - | Stock Option (Right to Buy) | |
| Savara Inc | Richard J. Hawkins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.65 per share. | 07 Dec 2022 | 1,172 | 1,900 (0%) | 0% | 0.7 | 762 | Common Stock |
| Lumos Pharma Inc | Richard J. Hawkins | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 8.75 per share. | 19 Sep 2022 | 1,506 | 2,047 (0%) | 0% | 8.8 | 13,178 | Common Stock |
| Lumos Pharma Inc | Richard J. Hawkins | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 8.65 per share. | 19 Sep 2022 | 541 | 541 (0%) | 0% | 8.7 | 4,680 | Common Stock |
| Lumos Pharma Inc | Richard J. Hawkins | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.23 per share. | 01 Apr 2022 | 1,466 | 748,243 (2%) | 0% | 9.2 | 13,531 | Common Stock |
| Lumos Pharma Inc | Richard J. Hawkins | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 35,400 | 35,400 | - | - | Stock Option (Right to Buy) | |
| Lumos Pharma Inc | Richard J. Hawkins | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 10.02 per share. | 01 Feb 2022 | 4,500 | 749,882 (2%) | 0% | 10.0 | 45,090 | Common Stock |
| Lumos Pharma Inc | Richard J. Hawkins | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.02 per share. | 01 Feb 2022 | 173 | 749,709 (2%) | 0% | 10.0 | 1,733 | Common Stock |
| Savara Inc | Richard J. Hawkins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Dec 2021 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Savara Inc | Richard J. Hawkins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Dec 2021 | 728 | 0 | - | - | Stock Option (Right to Buy) | |
| Savara Inc | Richard J. Hawkins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.55 per share. | 13 Dec 2021 | 728 | 728 (0%) | 0% | 0.5 | 400 | Common Stock |
| Lumos Pharma Inc | Richard J. Hawkins | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.25 per share. | 01 Apr 2021 | 1,522 | 745,382 (1%) | 0% | 12.3 | 18,645 | Common Stock |
| Lumos Pharma Inc | Richard J. Hawkins | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 28,475 | 28,475 | - | - | Stock Option (Right to Buy) | |
| Lumos Pharma Inc | Richard J. Hawkins | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 2,329 | 746,904 (2%) | 0% | 0 | Common Stock | |
| Savara Inc | Richard J. Hawkins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2020 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Plus Therapeutics Inc | Richard J. Hawkins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2020 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges